摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(3-吡啶基)-D-丙氨酸 | 70702-47-5

中文名称
3-(3-吡啶基)-D-丙氨酸
中文别名
H-Β-(3-吡啶)-DL-ALA-OH;(D)-3-吡啶苯氨酸;D-3-(3-吡啶基)-丙氨酸;(D)-3-吡啶丙氨酸;3-(3-吡啶基)-D-丙氨酸盐酸盐
英文名称
3-(3-pyridyl)-D-alanine
英文别名
d-3-pyridylalanine;(2R)-2-azaniumyl-3-pyridin-3-ylpropanoate
3-(3-吡啶基)-D-丙氨酸化学式
CAS
70702-47-5
化学式
C8H10N2O2
mdl
MFCD00079673
分子量
166.18
InChiKey
DFZVZEMNPGABKO-SSDOTTSWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    167-168 °C
  • 沸点:
    344.4±32.0 °C(Predicted)
  • 密度:
    1.271±0.06 g/cm3(Predicted)
  • 溶解度:
    1M HCl:10 mg/mL,澄清,无色
  • 稳定性/保质期:
    远离氧化物。

计算性质

  • 辛醇/水分配系数(LogP):
    -2.5
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    76.2
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    应将化学品存放在充有惰性气体的密封容器中,并存放于阴凉、干燥处。建议在2-8 ºC条件下保存。

SDS

SDS:dd6c20e13892f7c13ac3ac923db6e60b
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-(3-Pyridyl)-D-alanine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-(3-Pyridyl)-D-alanine
CAS number: 70702-47-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10N2O2
Molecular weight: 166.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(3-吡啶基)-D-丙氨酸N-甲基吗啉盐酸sodium hydroxide1-羟基苯并三唑盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺N,N'-二环己基碳二亚胺 作用下, 以 1,4-二氧六环氯仿 为溶剂, 反应 100.0h, 生成 1-(2-{2-[5-benzyloxycarbonylamino-2-(2-tert-butoxycarbonylamino-3-methyl-butyrylamino)-pentanoylamino]-4-methyl-pentanoylamino}-3-pyridin-3-yl-propionyl)-pyrrolidine-2-carboxylic acid methyl ester
    参考文献:
    名称:
    基于短杆菌肽s的低溶血抗微生物脱氢肽的合成。
    摘要:
    描述了一种新型的基于短杆菌肽S(GS)的环状β-折叠型抗菌脱氢肽的合成和生物学活性。使用Boc-Leu-通过溶液相方法合成了GS类似物,该类似物在4和4'位置(2)包含两个(Z)-(β-3-吡啶基)-α,β-脱氢丙氨酸(DeltaZ3Pal)残基。 DeltaZ3Pal内酯。类似物2显示出对革兰氏阳性细菌的高抗菌活性,并且比野生型GS和相应的(Z)-α,β-脱氢苯丙氨酸(DeltaZPhe)类似物(1)具有更低的溶血活性。
    DOI:
    10.1021/jm061051v
  • 作为产物:
    描述:
    N-acetyl-(β-3-pyridyl)-α,β-dehydroalanine 在 palladium on activated charcoal ammonium hydroxide 、 D-aminoacylase amano 、 氢气 作用下, 以 为溶剂, 反应 82.0h, 生成 3-(3-吡啶基)-D-丙氨酸
    参考文献:
    名称:
    基于短杆菌肽s的低溶血抗微生物脱氢肽的合成。
    摘要:
    描述了一种新型的基于短杆菌肽S(GS)的环状β-折叠型抗菌脱氢肽的合成和生物学活性。使用Boc-Leu-通过溶液相方法合成了GS类似物,该类似物在4和4'位置(2)包含两个(Z)-(β-3-吡啶基)-α,β-脱氢丙氨酸(DeltaZ3Pal)残基。 DeltaZ3Pal内酯。类似物2显示出对革兰氏阳性细菌的高抗菌活性,并且比野生型GS和相应的(Z)-α,β-脱氢苯丙氨酸(DeltaZPhe)类似物(1)具有更低的溶血活性。
    DOI:
    10.1021/jm061051v
点击查看最新优质反应信息

文献信息

  • Lipid probes and uses thereof
    申请人:THE SCRIPPS RESEARCH INSTITUTE
    公开号:US10168342B2
    公开(公告)日:2019-01-01
    Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    披露了用于识别脂质结合蛋白作为药物结合靶点的方法、组合物、探针、检测和试剂盒。此外,还披露了用于绘制脂质结合蛋白上的配体结合位点、识别脂质结合蛋白、生成药物-脂质结合蛋白轮廓、高通量药物筛选以及识别作为潜在脂质结合蛋白配体的药物的方法、组合物和探针。
  • Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors
    作者:David Harrison、Nicolas Boutard、Krzysztof Brzozka、Marta Bugaj、Stefan Chmielewski、Anna Cierpich、John R. Doedens、Charles-Henry R.Y. Fabritius、Christopher A. Gabel、Michal Galezowski、Piotr Kowalczyk、Oleksandr Levenets、Magdalena Mroczkowska、Katarzyna Palica、Roderick A. Porter、David Schultz、Marta Sowinska、Grzegorz Topolnicki、Piotr Urbanski、Jakub Woyciechowski、Alan P. Watt
    DOI:10.1016/j.bmcl.2020.127560
    日期:2020.12
    the NLRP3 inflammasome have been approved. In this work, we used the known NLRP3 inflammasome inhibitor CP-456,773 (aka CRID3 or MCC 950) as our starting point and undertook a Structure-Activity Relationship (SAR) analysis and subsequent scaffold-hopping exercise. This resulted in the rational design of a series of novel ester-substituted urea compounds that are highly potent and selective NLRP3 inflammasome
    NLRP3 炎症小体是先天免疫系统的一个组成部分,参与促炎细胞因子的产生。各种外源性和内源性信号的异常激活可导致慢性、低度炎症。由于与大量未满足医疗需求的疾病有关,如阿尔茨海默病、帕金森病、关节炎和癌症,它作为药物靶点引起了极大的兴趣。迄今为止,尚未批准专门针对抑制 NLRP3 炎症小体的药物。在这项工作中,我们使用已知的 NLRP3 炎症小体抑制剂 CP-456,773(又名 CRID3 或 MCC 950)作为我们的起点,并进行了结构-活性关系 (SAR) 分析和随后的支架跳跃练习。44和45。据推测,酯部分充当高渗透性的递送载体,随后被羧酸酯酶水解为羧酸活性物质。这些分子与最先进的技术有很大不同,并在治疗 NLRP3 驱动的疾病方面提供了潜力,特别是在需要组织穿透的情况下。
  • [EN] NEW AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS D'ACIDE AMINÉ, LEUR PROCÉDÉ DE PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:SERVIER LAB
    公开号:WO2016207226A1
    公开(公告)日:2016-12-29
    Compounds of formula (I): wherein R1, R2, R5, R6, R7, R12, X, Y, A, E and n are as defined in the description. Medicaments.
    式(I)的化合物:其中R1、R2、R5、R6、R7、R12、X、Y、A、E和n的定义如描述所示。药物。
  • [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
    申请人:NODTHERA LTD
    公开号:WO2018167468A1
    公开(公告)日:2018-09-20
    The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.
    本公开涉及式(I)的化合物及其药用可接受的盐、药物组合物、使用方法和制备方法。本文披露的化合物通过抑制炎症小体来抑制IL-1家族细胞因子的成熟,可用于治疗涉及炎症小体活性的疾病,如自身炎症和自身免疫疾病以及癌症等。
  • METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID
    申请人:HAMARI CHEMICALS, LTD.
    公开号:US20160102045A1
    公开(公告)日:2016-04-14
    Objects of the present invention are to provide an industrially applicable method for producing an optically active α-amino acid in high yield and in a highly enantioselective manner, to provide a simple production method of an optically active α,α-disubstituted α-amino acid, and to provide an intermediate useful for the above production methods of an optically active α-amino acid and an optically active α,α-disubstituted α-amino acid. The present invention provides a production method of an optically active α-amino acid or a salt thereof, the production method comprising introducing a substituent into the α carbon in the α-amino acid moiety of a metal complex represented by the following Formula (1): by an alkylation reaction, an aldol reaction, the Michael reaction, or the Mannich reaction, and releasing an optically pure α-amino acid enantiomer or a salt thereof by acid decomposition of the metal complex.
    本发明的目的是提供一种在高产率和高对映选择性的方式下生产光学活性α-氨基酸的工业上适用的方法,提供一种简单的生产方法,用于光学活性α,α-二取代的α-氨基酸,并提供一种用于上述光学活性α-氨基酸和光学活性α,α-二取代的α-氨基酸生产方法的中间体。本发明提供了一种光学活性α-氨基酸或其盐的生产方法,该生产方法包括通过烷基化反应、醛醇反应、迈克尔反应或曼尼希反应将取代基引入以下式(1)所表示的金属配合物的α-氨基酸基团的α碳中,并通过酸分解金属配合物释放光学纯α-氨基酸对映体或其盐。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物